Page 9 - Scientific Library
IDO and TDO - Cell based & biochemical assays
Â
Which roles do IDO and TDO play in Immunotherapy? Immune evasion is one of the identifying hallmarks of cancer and researchers are investigating the complex mechanisms that enable cancer cells to evade
Biomarkers associated to poor prognosis in pancreatic cancer
A recent publication by Torres et al. has found that B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer, and these
Immunotherapy Screening – OX40:OX40L pathway
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Neuromuscular diseases: A new application for Statins?
Statins are HMG-CoA reductase inhibitors, well-known  medications for treating Hypercholesterolemia. Simvastatin is a member of this "Statin family" and controls
Crosstalk between cancer and immune cells: tumor escape
A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer
Th17 cell-related Multiplex immunoassays
Classically, it was known that CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions to effect the
Cancer and immune cells crosstalk: immunoediting
Immunoediting of cytokine signals provides another area of pathways which tumours utilise to evade and potentially escape from immunological targeting. This post aims at shedding some light into the
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,
2 assays to assess GEF and GAP activity
In my previous post Small GTPases: Measuring small G protein activation I looked at state-of the-art methods for measuring the activation of small G proteins, such as RhoA, Rac1, Cdc42, and the proto-oncogen
Following your proteins - anti-tag antibodies (I)
When producing recombinant proteins, one can follow the purification process either by antibodies detecting the target protein specifically, or by adding a tag to it, thus using antibodies detecting not